CORRECTING and REPLACING OncoSec Medical to Present at Prominent Scientific and Investment Conferences in March
March 04 2015 - 11:37AM
Business Wire
The date in the second paragraph, second sentence should read
Wednesday, March 11th (instead of Wednesday, March 8th).
The corrected release reads:
ONCOSEC MEDICAL TO PRESENT AT PROMINENT
SCIENTIFIC AND INVESTMENT CONFERENCES IN MARCH
OncoSec Medical Inc. (OTCQB: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, announced today that
it will present at several high-profile events in March, including
the 27th Annual ROTH Conference and the 5th Annual "Cancer
Immunotherapy: A Long- Awaited Reality" Conference.
27th Annual ROTH Conference
Punit Dhillon, President and CEO, will present a corporate
overview at the 27th Annual ROTH Conference, which is held March
8-11 in Dana Point, CA. The presentation is scheduled to begin at
8:00 AM PT on Wednesday, March 11th in the Colonnade Room on Track
4.
Each year, the ROTH Conference gathers institutional investors,
private equity investors, company executives and service providers
to build relationships and provide a platform for networking with
existing and potential clients. The conference features
presentations from hundreds of public and private companies in a
variety of sectors, including healthcare, business services,
consumer, and industrial growth. For more information, please
visit: http://www.roth.com.
OncoSec invites investors and the general public to view and
listen to the live webcast. At the time of the presentation, the
webcast will be available via the following link:
http://wsw.com/webcast/roth29/oncs. Please register at least 10
minutes prior to the start of the presentation to ensure timely
access. After the presentation, an archived version of the webcast
will be available for 90 days on OncoSec’s website:
http://www.oncosec.com.
5th Annual "Cancer Immunotherapy: A Long-
Awaited Reality" Conference
Robert H. Pierce, MD, Chief Scientific Officer, will present a
corporate overview as well as a lecture, entitled: "Taking the
Fight to the Tumor: A Rationale for Intratumoral Electroporation of
Immunomodulators” at MaidStone Life Sciences’ 5th Annual "Cancer
Immunotherapy: A Long-Awaited Reality" Conference on Thursday,
March 26th at the New York Academy of Medicine in New York City.
Dr. Pierce will also join key opinion leaders to discuss the role
of cancer vaccines in a panel discussion, entitled "What Is the
Role of Cancer Vaccines in an Environment Overwhelmed by Checkpoint
Inhibitors and T-Cell Immunotherapies?”
The annual "Cancer Immunotherapy: A Long-Awaited Reality" is a
single-day conference that unites founding visionary researchers,
clinicians, business leaders, key investors, and other stakeholders
to engage in discussions and showcase leading companies in the
field of cancer immunotherapy. The conference format is designed to
foster networking, knowledge sharing, and learning in an
interactive environment. For more information, please visit:
http://www.maidstonels.com/conference.html.
About OncoSec Medical
OncoSec Medical Inc. is a biopharmaceutical company developing
its investigational ImmunoPulse intratumoral cancer immunotherapy.
OncoSec Medical's core technology is designed to
enhance the local delivery and uptake of DNA IL-12 and
other DNA-based immune-targeting agents. Clinical studies of
ImmunoPulse have demonstrated an acceptable safety profile and
preliminary evidence of anti-tumor activity in the treatment of
various skin cancers, as well as the potential to initiate a
systemic immune response limiting the systemic toxicities
associated with other treatments. OncoSec's lead program evaluating
ImmunoPulse for the treatment of metastatic melanoma is currently
in Phase II development, and is being conducted in collaboration
with several prominent academic medical centers. As the company
continues to evaluate ImmunoPulse in its current indications, it is
also focused on identifying and developing new immune-targeting
agents, investigating additional tumor indications, and evaluating
combination-based immunotherapy approaches. For more information,
please visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
OncoSec Medical Inc.Investor Relations:Jordyn Kopin,
855-662-6732investors@oncosec.comorMedia Relations:Mary Marolla,
855-662-6732media@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024
